Navigation Links
Regado Biosciences' REG1 Anticoagulation System Study Results Published in the Journal of Thrombosis and Haemostasis
Date:5/14/2008

in a prestigious, clinically oriented, peer-reviewed publication."

Results from Regado's 1c study were presented previously at the American Heart Association's 2007 Scientific Sessions.

About REG1 Anticoagulation System Clinical Program

In the Phase 1c clinical study, the researchers randomized 39 healthy volunteers to receive either three consecutive REG1 treatment cycles or placebo. Each REG1 cycle consisted of an intravenous (IV) bolus of RB006 dosed at 0.75 mg/kg, followed an hour later by a descending dose of RB007, ranging from a 2:1 to 0.125:1 antidote:drug ratio (1.5 mg/kg to 0.094 mg/kg of RB007). Clinical and coagulation assessments were measured for 14 days.

The Phase 1 program included two additional studies. A Phase 1a study enrolled 84 healthy volunteers, while a Phase 1b study enrolled 50 patients with stable coronary artery disease who were receiving aspirin with or without clopidogrel. The results showed an IV bolus injection of RB006 achieved, in both study populations, a prompt, consistent, and dose-dependent prolongation of activated partial thromboplastin time (aPTT). In addition, a 1 mg/kg dose of RB006 resulted in essentially complete Factor IXa inhibition. The studies also demonstrated an IV bolus injection of RB007 administered in a 2:1 antidote:drug ratio successfully reversed prolonged aPTT within a median of one minute, with no rebound increase up to seven days. Despite dual antiplatelet use in 19 subjects, there were no major bleeding or other serious adverse events observed in either study.

Based upon the combined results of the Company's Phase 1a, 1b, and 1c studies, Regado initiated REVERSAL-PCI, a multi-center, open-label, randomized Phase 2a clinical study of the REG1 anticoagulation system. The Phase 2a study is enrolling 26 patients undergoing elective percutaneous coronary intervention (PCI) to assess whether REG1 can replace standard heparin therapy during the performance of coronary balloon an
'/>"/>

SOURCE Regado Biosciences
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Neurocrine Biosciences to Present at the 2008 Citi Investment Research Global Health Care Conference
2. Kosan Biosciences to Present at the Leerink Swann Solid Tumors Roundtable Conference
3. YM BIOSCIENCES ANNOUNCES PRESENTATIONS FOR AEROLEF(TM) AT AMERICAN PAIN SOCIETY ANNUAL MEETING
4. Pressure BioSciences, Inc. to Discuss First Quarter 2008 Financial Results and Provide Business Update
5. Sangamo BioSciences Nominates Thomas G. Wiggans to Its Board of Directors
6. Sangamo BioSciences Announces First Quarter Conference Call and Webcast
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2008 Financial Results
8. Monogram Biosciences Announces First Quarter 2008 Financial Results Conference Call
9. Monogram Biosciences to Present at the JMP Securities Seventh Annual Research Conference
10. YM BIOSCIENCES ANNOUNCES PRESENTATIONS FOR TWO OF ITS ANTI-CANCER DRUGS AT AACR ANNUAL MEETING
11. Raven biotechnologies Announces Collaboration With Monogram Biosciences to Advance Diagnostic Cancer Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Xeno ... Excellence following its most recent COLA inspection. Xeno ... COLA, a national healthcare accreditation organization. Accreditation is ... of quality in day-to-day operations, demonstrate continued accuracy ... a rigorous on-site laboratory survey. , ...
(Date:12/17/2014)... Audacity, a leading California-based health and ... the Huntsworth Health Group, is proud to announce the ... her role, Gonzales will serve as Senior Vice President ... to welcome a talent of Jamie’s caliber to the ... “She is a proven healthcare innovation leader and brand ...
(Date:12/17/2014)... , Dec. 17, 2014  United Therapeutics Corporation ... executive promotions as well as changes to Martine ... Executive Promotions United Therapeutics announced the ... and Co-Chief Executive Officer and David Zaccardelli , ... In connection with these promotions, Dr. Rothblatt,s title will ...
(Date:12/17/2014)... Dec. 17, 2014 Tigercat Pharma, Inc. ... study evaluating the investigational oral NK-1 receptor antagonist ... severe, chronic itch who are unresponsive or inadequately ... topical steroids and antihistamines. The ... Analog Scale (VAS) itch score from baseline, comparing ...
Breaking Biology Technology:Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 3United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4
... clot-forming platelets every day, but there are times when ... diseases or during invasive surgery. Now, University of Pennsylvania ... bone marrow cells called megakaryocytes to quadruple the number ... student of pharmacology in Penn,s Perelman School of Medicine, ...
... Warwick Department of Physics has been awarded a prestigious ... "Creating Silicon Based Platforms for New Technologies". The initiative ... to "cooltronics", enabling zero-power electronics and could be key ... million Platform Grant from the Engineering and Physical Sciences ...
... At an atomic scale, the tiniest bridge of gold -- ... strongest, according to new research by engineers at the University ... the result of experiments probing the characteristics of atomic-scale necks ... a cantilever was pushed into a flat, gold surface. An ...
Cached Biology Technology:Penn researchers show single drug and soft environment can increase platelet production 2Penn researchers show single drug and soft environment can increase platelet production 3Warwick wins $2.7 million research grant to help 'cooltronics' 2Narrowest bridges of gold are also the strongest, study finds 2
(Date:12/19/2014)... 18, 2014 Research and Markets ( ... "Micro Market Monitor: North America Perimeter Security Systems Market" ... http://photos.prnewswire.com/prnh/20130307/600769 The North American perimeter ... of 3.6% from 2014 to 2019. Although the U.S. ... Canada is expected to grow at ...
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ... "Samsung Galaxy S5 - Home Button Synaptics Fingerprint ... http://photos.prnewswire.com/prnh/20130307/600769 ... than the iPhone 5S, Samsung introduces for the ... The Galaxy S5 home button presents ...
(Date:12/17/2014)... RALEIGH, N.C. , Dec. 16, 2014 ... has licensed its PerformTek biometric technology to industry leaders ... their highly accurate, clinically validated, biometric wearable products. These ... January 6-9 in Las Vegas . ... the technology is accurate, flexible and robust – with ...
Breaking Biology News(10 mins):Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... April issue of the Journal of the American ... eating plans; dietary quality among children; and relationships between ... Increased Risk of Eating Disorders , While vegetarians tend ... non-vegetarians to be overweight or obese, they may be ...
... the Richard King Trainee Award. This award was instituted last ... to encourage ABMG trainees in their careers and to foster ... year the editorial board will review all articles published in ... or corresponding author during that year. The manuscript felt to ...
... Being able to accurately predict how a given ... non-responsive tumors the burden of undergoing toxic and ultimately ... a patient,s cancer-causing genetic lesions are contributing to drug ... Researchers led by Professor Scott Lowe, Ph.D., ...
Cached Biology News:News from the April 2009 Journal of the American Dietetic Association 2Jonathan Berg, M.D., Ph.D. awarded Richard King Trainee Award for Best in Genetics in Medicine 2CSHL team develops mouse models of leukemia that predict response to chemotherapy 2CSHL team develops mouse models of leukemia that predict response to chemotherapy 3CSHL team develops mouse models of leukemia that predict response to chemotherapy 4
Mouse monoclonal [PRMT5-21] to PRMT5 ( Abpromise for all tested applications). entrezGeneID: 10419 SwissProtID: O14744...
Mouse Serpin F1/PEDF MAb (Clone 199315)...
Human CCL26/Eotaxin-3 MAb (Clone 115002)...
Human TFPI Affinity Purified Polyclonal Ab Protein Family: Coagulation, Inflammation, Serine Protease Regulators...
Biology Products: